XVI IAS Video Library Page


		William E Arnold, CEO and Vice Chair, Title II Community AIDS National Network, (T2CANN)	Bill languishes over the cost of medical care, increases in the HIV population, and most importantly how to pay for the newly infected populations treatment, in face of the deployment of aggressive testing campaigns in many cities. Global ACCESS

		A Cornelius Baker, National Policy Advisor, National Black Gay Men's Advocacy Coalition, Washington, DC	Cornelius describes his early and current focus on activism in HIV/AIDS both in this country and worldwide. His eloquence in advocacy has be powerful in the many issues he has be empowered to engage in.

		Chris Beyrer, MD, MPH, Director, Center for Public Health and Human Rights, Bloomberg School of Public Health, Johns Hopkins, University, Baltimore, Maryland	Chris Covers the epidemiology of HIV Disease including causation, prevelence and risk which dramatically makes the case for urgent interventions

		Louise Binder, Activist, Toronto, Ontario, Canada	Louise reveals her beginning and passions in HIV Activism. In addition to being the opening plenary speaker, she has had a remarkable activist career in Activism building advocacy in Canada and worldwide collaborations that have led the fight for HIV/AIDS especially for women’s issues. Interviewer: Interview by Cathy Olufs, Education Director, Center for Health Justice, Los Angeles, California

		Patrick Bouic, Professor, Chief Technical Officer, Synexa Life Sciences, Cape Town, South Africa	Patrick describes a new immune based therapy which is making it’s way into the AIDS Treatment Pipeline

		Richard Burzynski, Executive Director, International Council of AIDS Service Organizations, (ICASO) Toronto, Canada	Richard presents the extraordinarily diverse populations and service organizations with which ICASO works. Policy issue changes are evaluated and exposed at AIDS 2010 by ICASO and other organizations to improve access and treatment in a most practical and certain scientific approach.

		Canon Gideon Byamugisha, Advisor, World Vision, Church and Faith-Based Partnerships, Namirembe, Uganda	Gideon is one of the leaders of the spiritual community who is leading the fight to stop stigma of all people living with AIDS by example. This project is expanding to other Countries around the world as the World Vision has the capacity to do so.

		Pedro Cahn, MD, Chief, Infectious Diseases Unit, Juan A Fernandez Hospital, Assistant Professor, Infectious Diseases, Buenos Aires University Medical School, IAS President 2010-2010	Dr. Kahn, presents the focus of the upcoming International AIDS Conferences. He supports the hard scientific data which is presented in Toronto but make it clear that all the other social issues are really at the heart of the advances in awareness that are critically important to the overall fight for an answer to AIDS.

		Linda Cauperauld, Executive Director, Canadian Federation for Sexual Health, Ottawa

		Yvonne Chaka Chaka, Princess of Africa, Vocal star and Global Health Advocate, on the African Continent	Yvonne describes the plight of people in Africa which extends beyond AIDS to Malaria and TB. She advocates through educational messages and appropriate use of limited human and financial resources for all people of Africa.

		Dr. Emile Hérald Charles, Directeur du Programme Santé, Fondation Sogebank, Programme Fonds Mondial, Pétion-Ville, Haiti	Interview in Haitian

		Manju Chatani, Coordinator, African Microbicides Advocacy Group (AMAG), Accra cc Ghana	Manju has championed the concept of microbicides, firmly believing that the advocacy and demand for research has caused the research to become more fully funded. She works with other advocacy groups and other community organizations to be the decision makers, developing the research outcome criteria.

		David Cooper, MD, Saint Vincents Medical Center, Sydney, Australia	David is principal investigator on a Johnson and Johnson Rybozyme Phase II trial which is being conducted in Saint Vincents/Sydney, Stamford and UCLA. The trial will be completed in late 2010. He also weighs in on the outcome of the Smart Study and what may be alternatives to treatment interruption.

		Dr Kim Eva Dickson	Dr. Dickson is working in a newly created field, looking at PEP, Microbicdes and innovative prevention technoligies. She advocates for the choices which will work in a more global context.

		Richard Elion, MD, Associate Clinical Professor of Medicine. George Washington University School of Medicine, Washington, DC	Discussing treatment selection the naïve populations, as well as second and third treatment regimens and some attention to the concept of single pill treatment. He’ll also cover the importance and management of adherence.

		Anthony Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland	As the US government leader of the science in AIDS, he covers the very important prevention message, the reponse to activist issues and the hope for the new ARV targets as well as micobicides and vaccines.

		Robert Fox, Executive Director, Oxfam Ottawa, Ontario, Canada, (Oxford Committee for Famine Relief)	Oxfam Canada builds lasting solutions to global poverty and injustice. Oxfam Canada believes that people together can create a fair world, free of poverty and injustice.

		Jacqueline C Gahagan PhD, Associate Professor, Health Promotion, School of Health and Human Performance, Dalhousie, University, Halifax, Nova Scotia, Canada	Jacqueline represents the subject of the impotance of treatment access and research in Women in Canada.

		Helene Gayle, MD, Chair Co-Chair, AIDS 2010, President, International AIDS Society, President, CEO, CARE USA	Helene Gayle provides a brief background to her commitment to AIDS

		Stuart Gillespie, Ph.D. Director, RENEWAL, International Food Policy Research Institute (IFPRI)	Stuart’s focus is scaling up the policy and knowledge about access to and the building of a sustainable nutritional plan basic food for developing countries.

		Anand Grover, Director, Lawyers Collective HIV/AIDS Unit, New Delhi, India	Anand is advocating for the rights of individuals from a legal perspective to decriminalize sex workers and other individuals who are HIV positive who need access to HIV medicine. He is also working to change the form of otherwise patented drugs to gain access for people living in the developing world to needed second generation HIV treatments.

		Polly F Harrison, PhD, Director, Alliance for Microbicide Development, Silver Spring, Maryland	Polly chats with Jim about the somewhat surprising attention that is given to the Microbicide field at the AIDS Conference.

		Reverend Father Japé Heath, General Secretary, African Network of Religious Leaders Living with or Personally Affected by HIV and AIDS (ANERELA+), Johannesburg, South Africa	Father Japé covers the support structure, positive information and discrimination policy that is key to the mission of ANERELA. His goal is to challenge the stigma that evolves mostly from the faith-based community

		Bernard Hirschel, MD, Médecin adjoint, Hôspitaux Universitaires de Genève, Genève, Switzerland	Background of last 10 years,treatment interruption, single treatment use

		Jon D Kaiser, MD, UCSF Medical School, San Francisco, California, USA	Jon speaks about his presentation at the conference on the micronutrient study, and potential clinical application of nutritional supplementation.

		Eugenia Leon	Interviewed by Louis Fernando Lial, Bogota, Columbia. Language: Spanish

		George Saavedra Lopez, Director General, Mexico National AIDS Program	Director General Lopez, presented his country's current plan to treat all people living with HIV/AIDS through the Mexico National healthcare program through and over 100 program physician.

		Anuar Luna, Project Coordinator, Mexico City, Mexico and Oswaldo Rada, Regional Secretary, REDLA	Interview in Spanish

		Janak K Maniar, MD, DVD, DDV, Consulting Physician in HIV Medicine, Bhatia General Hospital, Mumbai, India	Dr. Maniar presented at the International AIDS Conference on the struggle to control the TB epidemic in India due to uncontrolled droplet dissemination and the drug resistant TB strains

		Ian McGowan, MD, PhD, FRCP, Co-Director, UCLA Center for HIV and Digestive Diseases, Professor of Medicine, Los Angeles California	Ian covers the broad areas of microbicides of both rectal and vaginal, trials, new networks and some of the political and social concerns for conducting trials, microbicide use, as well as funding through governments, corporations and foundations.

		Veadimir Mendelevich, Russia Medical University, Kazan, Russia	Inna Dubinsky, Special Correspondent, Voice of America, Washington, DC Language: Russian

		Mark Mitchnick, MD, Senior Scientific Consultant, International Partnership for Microbicides, (IPM) Silver Springs, Maryland	Background and discussion of Microbicides- Mark provides a background on the design and use of vaginal and anal microbicides and the importance of the development. He also covers the construct of the pipeline and sense of availability to those who need to use them. www.ipm-microbicides.org

		Siphokazi Mthatih	Siphokazi hits hard on the misinformation and denialism of her own government. She focuses on the fact that we know we can treat AIDS we just have to make it happen.

		Anders Nordström, MD Acting Director-General, World Health Organization (WHO)	Anders describes his increased attention to intellectual property issues, healthworkers and especially prevention care and treatment.

		Leigh Peterson, PhD, Senior Scientist, Institute for Family Health, Family Health International, Project leader Oral Tenofovir Study	She covers the study which was prematurly stopped in Camaroon. She will explain how the study still provided some useful information in the remaining sites.

		Arletty Pinel, Chief, Reproductive Health Branch, United National Population Fund, New York, New York	Arletty speaks very powerfully about the comprehensive maternal needs of treatment, care and support which is required to boldly address this global issue.

		Anbumani Ramadoss, MD, Minister for Health and Family Welfare, Government of India, New Delhi, India	With 2 million cases Anbumani has revealed the strategy to focus largely on prevention efforts especially in the youths of India.

		Rev Edwin C Sanders II, Senior Servant, Metropolitan Interdenominational Church, Nashville, Tennessee	Rev Sanders collaborates with a distinguished list of leaders who advocate for and motivates the participation African Americans in AIDS Vaccine clinical trials. Interviewer: Sam Averett, Board member, AIDS Vaccine Advocacy Coalition.

		Myrto Schaefer, MD, MSc, (Head of Project Unit, Médecins Sans Frontier's, . Médecins Sans Frontier's au sujet des enfants avec le SIDA	Experience treating children with AIDS
			Language: Français (Interviewer) - Fernando Pascual

		Mariângela Batista Galvão Simão, Diretora do Programa Nacional de DST-AIDS, Ministério de Saúde, Brasil	Interview in English
			Entrevistada por Michel Lotrowska, MSF (Médicos Sem Fronteiras) Desafios sobre a sustentabilidade e universalidade do Programa de Aids Brasileiro . Language: Português

		Paul Stoffels, MD, Company Group Chairman, Worldwide Research & Development Pharmaceuticals Group, Johnson and Johnson, Belgium	Paul takes us to the roots of his passion to deliver results in development of effective HIV treatment quickly by placing the bar much higher than normal industry standards.

		Jeffrey L. Sturchio, Vice President, External Affairs, Human Health International, Merck, Whitehouse Station, New Jersey	Jeffrey provides a background for the new Merck integrase inhibitor, and it’s encouraging phase II data and expanded access for this new compound. He also covers his perspective of access to treatment worldwide over the last ten years of HAART

		Marcie Summers, Executive Director, Positive Women's Network, Vancouver, Canada	Marcie and Linda present the issues that face women in Canada and the world have to face in sexual relationships. They present some of the practical HIV prevention strategies that they have been advocating for at the Conference.

		Mark A Wainberg, OC, OQ, PhD, Co-Chair AIDS 2010, Director, McGill University AIDS Centre and Professor of Medicine and Microbiology	Mark provides some of the conference statistics as well as the dramatic social statistics that are brought to the conference to be pressed for urgent results.

		Jens Wenkel MD, Medecins Sans Frontieres, Practicing at the MSF Clinic in Lagos, Nigeria	Jens covers the activism that is necessary to respond to the recent and growing evidence that the first line is no longer effective in the developing world, representing a dire and immediate need for second line treatment.

		Phil Wilson, Executive Director, Black AIDS Institute	Phil is one of the leading advocates who currently focuses exclusively at empowerment of the black population to fight for access to comprehensive prevention programs, testing, early treatment and services.

		Paul Zeitz, Executive Director, Global AIDS Alliance, Washington, DC	Paul discusses science based prevention advocacy, universal prevention education, treatment and pediatric treatment access issues, as well as the concerns for the long-term sustainability of treatment and treatment access.